Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 12—December 2005


Porcine Noroviruses Related to Human Noroviruses

Qiu-Hong Wang*, Myung Guk Han*, Sonia Cheetham*, Menira Souza*, Julie A. Funk†, and Linda J. Saif*Comments to Author 
Author affiliations: *The Ohio State University, Wooster, Ohio, USA; †The Ohio State University, Columbus, Ohio, USA

Main Article

Table 4

Antigenic cross-reactivity between human GII NoV antigens (VLPs) and a pig convalescent-phase antiserum against porcine GII NoVs, as determined by ELISA*

Antiserum ELISA antibody titer with each VLP antigen (genogroup-genotype)
(GII-1) Toronto (GII-3) MD145 (GII-4) HS66 (GII-4) Florida (GII-6) Desert Shield (GI-3)
HS66CS (positive control): human convalescent antiserum to human HS66 (GII-4) 1:25,600 1:6,400 1:25,600 1:25,600 1:6,400 1:6,400
LL616: pig convalescent-phase antiserum to porcine QW126 (QW101-like, GII-18)† 1:100 1:800 1:400 1:400 1:400 1:10
LL368 (negative control): preinoculation serum‡ <1:10 <1:10 <1:10 <1:10 <1:10 <1:10
MM982 (negative control): preinoculation serum‡ <1:10 <1:10 <1:10 <1:10 <1:10 <1:10

*NoV, norovirus; VLP, viruslike particle; ELISA, enzyme-linked immunosorbent assay.

†The QW126 shared 99% and 100% amino acid identities to the QW101 strain (GII-18) for a 169-bp segment in the RNA-dependent RNA polymerase region and a 363-bp segment in the capsid region, respectively.

‡LL368 and MM982 were sera from 2 gnotobiotic pigs before inoculation with porcine NoVs.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO